Cost-effectiveness analysis of leadless cardiac resynchronization therapy.

Nadeev Wijesuriya Vishal Shahil MehtaFelicity De VereSandra HowellJonathan M BeharAndrew ShuteMichael LeePaolo BoscoSteven A NiedererChristopher A Rinaldi

Published in: Journal of cardiovascular electrophysiology (2023)

Within the model limitations, these findings support the use of WiSE-CRT in indicated patients from an economic standpoint. However, improving battery technology should be prioritized to maximize cost-effectiveness in times when health services are under significant financial pressures.

Keyphrases

cardiac resynchronization therapy
end stage renal disease
left ventricular
heart failure
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
healthcare
patient reported outcomes
young adults
patient reported